Bulk Pharmaceutical API Sources for IMBRUVICA

Bulk Pharmaceutical API Sources for IMBRUVICA

Vendor	Vendor Homepage	Vendor Sku	API Url
MedChemexpress MCE		HY-10997
AbaChemScene		CS-0015
Molport		MolPort-027-806-955
AKos Consulting & Solutions		AKOS022185476
Axon Medchem		1858
BOC Sciences		936563-96-1
ChemShuttle		104516

Bulk Active Pharmaceutical Ingredient (API) Sources for IMBRUVICA

Last updated: February 19, 2026

IMBRUVICA (ibrutinib) is a Bruton’s tyrosine kinase (BTK) inhibitor indicated for various hematologic malignancies. It is marketed by Pharmacyclics, an AbbVie company. The quality and supply of the active pharmaceutical ingredient (API) are critical for manufacturing, regulatory compliance, and supply chain stability.

API Manufacturing and Supply Chain Overview

Ibrutinib API is synthesized through complex chemical pathways requiring high purity standards. Key players involved in API production include contract manufacturing organizations (CMOs) and API suppliers recognized for compliance with good manufacturing practices (GMP).

Major API sources are primarily based in Asia, with companies in China, India, and South Korea being predominant.

Prominent API Suppliers for Ibrutinib

Supplier Name	Location	GMP Certification	Annual Production Capacity	Key Strengths	Notable Features
WuXi STA (WuXi AppTec)	China	Yes	Estimated 10–20 kg/month	Extensive experience in complex APIs	Analytic and process development; large manufacturing footprint
Zhejiang Hisun Pharmaceutical	China	Yes	Approx. 10 kg/month	Cost-effective API production	Focus on oncology APIs
Jubilant Life Sciences	India	Yes	Estimated 5–15 kg/month	Proven track record in generic APIs	Stringent quality controls
Hetero Labs	India	Yes	5–10 kg/month	Focus on oncology and chemotherapeutic APIs	Established regulatory compliance
Jiangsu Hengrui Medicine	China	Yes	Limited; custom/private	R&D-focused, GMP-certified facilities	Recent entry into large-scale production

API Sourcing Considerations

• Quality Assurance: Suppliers must hold GMP certifications, typically from the U.S. FDA, EMA, or equivalent regulatory bodies.
• Documentation: Dossiers including Certificate of Analysis (CoA), stability data, and batch records are critical.
• Supply Reliability: Capacity to scale to meet global demand and contingency plans for shortages or disruptions.
• Regulatory Acceptance: APIs must meet the standards specified in the recognized drug master files (DMFs) or equivalent filings.

Regulatory Aspects

Manufacturers and suppliers submit API documentation for regulatory review by agencies such as the FDA or EMA. These submissions include vendor qualification, process validation, and biological safety data.

Any change in API source typically requires a regulatory notification or variation submission to ensure continued approval of IMBRUVICA.

Market Dynamics and Trends

• API sourcing for IMBRUVICA is shifting toward increased diversification to mitigate supply risks.
• API manufacturers in China and India dominate owing to cost advantages and scale.
• Recent regulatory tightening has increased focus on supply chain transparency and chemical process validation.

Summary of API Supply Chain Risks

• Political and Trade Policies: Tariffs, export restrictions, or bans can impact supply.
• Quality Compliance: Non-compliance risks delays or regulatory penalties.
• Capacity Constraints: Rapid market growth or supply disruptions can limit availability.
• Environmental and Safety Regulations: Changes in environmental standards may impact production costs or licensing.

Key Takeaways

• The primary API sources for IMBRUVICA are suppliers in China and India, with certifications and capacity to meet regional and global demands.
• Suppliers are selected based on GMP compliance, proven quality, and supply reliability.
• Supply chain diversification and regulatory vigilance mitigate risks associated with API sourcing.

FAQs

1. Which suppliers are most commonly used for IMBRUVICA API?
WuXi STA, Zhejiang Hisun, Jubilant Life Sciences, Hetero Labs, and Jiangsu Hengrui are key API suppliers with GMP certification and capacity for large-scale production.

2. What quality standards are required for IMBRUVICA API suppliers?
Suppliers must comply with GMP standards from recognized authorities such as the FDA, EMA, or WHO. Certificates of Analysis and process validation documents are essential.

3. How does API sourcing impact regulatory approval?
Regulatory agencies review API approval documentation, including supplier qualification and validation data. Changes in API sources typically require submission of variations or amendments.

4. What are the main risks in the API supply chain for IMBRUVICA?
Risks include political disruptions, quality non-compliance, capacity limitations, and environmental regulations affecting production.

5. How do manufacturers ensure API supply chain stability?
Through supplier diversification, maintaining multiple qualified vendors, and establishing contingency plans for shortages or delays.

References

1. FDA Drug Master Files. (2022). FDA. https://www.fda.gov/drugs/drug-master-files-dmfs
2. EMA Certificate of GMP Compliance. (2022). European Medicines Agency. https://www.ema.europa.eu/en/human-regulatory/overview/gmp-certificates
3. WuXi AppTec. (2022). Capabilities in API production. https://www.wuxiapptec.com
4. Zhejiang Hisun Pharmaceutical. (2022). API manufacturing overview. http://www.hisunpharm.com
5. Indian API Manufacturers Association. (2022). Industry reports. https://www.ima-india.org